Challenging the drug development blueprint: A formulator's perspective
By John G. Augustine, Ph.D.
By increasing the number of viable programs from discovery and early development into preclinical testing, it may be possible to increase the probability of success during the transition into clinical testing and through the approval process. Innovatively applying concepts and tools from formulation development earlier can add formulation criteria to the selection process and help inform the selection of an API for continued development.
In a new white paper from SP Formulations, titled “Challenging the drug development blueprint: A formulator's perspective”, Dr. John Augustine, Formulations Manager, offers practical advice that can help to increase the likelihood of successful drug development.
To download the white paper, please fill out the form below.
